Comments on:

FDA reviews 2 promising new drugs for hepatitis C

Back to the article » By |
WASHINGTON (AP) — Doctors may soon have two new drug options to treat patients with hepatitis C, just as the liver-destroying virus becomes a major public health issue for millions of baby boomers. The Food and Drug Administration holds a public meeting this week to review two experimental medications from Johnson & Johnson and Gilead Sciences. The new drugs, if approved, could offer...